Using immune cell testing to guide cytomegalovirus prevention after lung transplant
Follows immune response to cytomegalovirus in adults who received a lung transplant.
Key facts
- Who runs it
- University of Miami
- Where
- Miami, United StatesSee the site
- Trial code
- Registry title
- Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 3 Jul 2024
- Expected to end
- 30 Dec 2026
- Type of study
- Observational
- Record updated
- 23 March 2026
Who can take part
The trial is looking for adults waiting for a lung transplant who have had past CMV infection, shown by a blood test. The trial follows their immune response to CMV (cytomegalovirus) for 1 year.
- Age
- 18 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- People expected to receive a lung transplant, either double lung or single lung.
- Biomarker or test result
- Positive CMV IgG blood test before the transplant (a sign of past CMV infection).
- Main reasons for not taking part
- Negative CMV IgG before the transplant
- Pregnant or breastfeeding women
- People with HIV infection
- People waiting for a combined organ transplant, such as lung-heart or lung-kidney
This trial only enrols participants who have had an organ transplant. The registry sentence this rests on: Anticipated to receive a lung transplant (both double lung and single lung)
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- Adult patients over 18 years of age
- Lung transplant candidates with positive CMV IgG
- Anticipated to receive a lung transplant (both double lung and single lung)
Who cannot take part
- Negative CMV IgG prior transplant
- HIV infected patients
- Combined organ (e.g., lung-heart, lung-kidney) transplant candidates
- Pregnant or breastfeeding women
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Lung diseases
This trial is currently available in United States.
- University of MiamiMiami, United StatesContact: Yoichiro Natori, MDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response based on the Cytomegalovirus (CMV) virus testing.
The group in the trial
- Prophylaxis guided by Cytomegalovirus-specific T cell Immunity
The immunological response of participants in this group will be followed for 1 year.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients: a Single Center Prospective Study
- Plain-language title
- Using immune cell testing to guide cytomegalovirus prevention after lung transplantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT06494033, who can take part
- Record updated
- 23 March 2026